Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DUT | P33316 | 1/20 | 0.40 |
| ▸ | NLRP3 | Q96P20 | 2/20 | 0.38 |
| ▸ | P2RY6 | Q15077 | 7/20 | 0.37 |
| ▸ | P2RY2 | P41231 | 5/20 | 0.37 |
| ▸ | P2RY4 | P51582 | 5/20 | 0.37 |
| ▸ | HRAS | P01112 | 1/20 | 0.35 |
| ▸ | ABL1 | P00519 | 1/20 | 0.33 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.33 |
| ▸ | NT5E | P21589 | 1/20 | 0.33 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10376855 | 0.90 | MAPT (0.40) | DUTNLRP3P2RY6P2RY2P2RY4 | |
| SCHEMBL4285392 | 0.82 | LMNA (0.43) | DUTP2RY6P2RY2P2RY4ABL1 | |
| SCHEMBL10590553 | 0.80 | MAPT (0.36) | DUTP2RY6P2RY2P2RY4HRAS | |
| SCHEMBL10512100 | 0.79 | DUT (0.37) | DUTP2RY6P2RY2P2RY4HRAS | |
| SCHEMBL4285526 | 0.78 | LMNA (0.39) | DUTNLRP3P2RY6HRASNT5E | |
| SCHEMBL10377222 | 0.77 | ROCK2 (0.39) | DUTP2RY6HRASABL1RIN1 | |
| SCHEMBL10378300 | 0.76 | PTGS2 (0.37) | DUTP2RY6HRASABL1RIN1 | |
| SCHEMBL10509560 | 0.76 | ABL1 (0.43) | DUTP2RY6P2RY2P2RY4ABL1 | |
| SCHEMBL10376854 | 0.76 | MAPT (0.38) | DUTP2RY6P2RY2P2RY4ABL1 | |
| SCHEMBL1879258 | 0.74 | DUT (0.65) | DUTNLRP3P2RY6P2RY2P2RY4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140031309-A1 | Beta-L-N4 Hydroxycytosine Deoxynucleosides and their use as Pharmaceutical Agents in the Prophylaxis or Therapy of Viral Diseases | MAX-DELBRUECK-CENTRUM FUER MOLEKULARE MEDIZIN (DE) | 2014-01-30 | — | — | US | disclosed |
| US-20090105186-A1 | Beta-L-N4-Hydroxycytosine Deoxynucleosides and their use as Pharmaceutical Agents in the Prophylaxis or Therapy of Viral Diseases | MAX-DELBRUECK-CENTRUM FUER MOLEKULARE MEDIZIN (DE) | 2009-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105186-A1 | Beta-L-N4-Hydroxycytosine Deoxynucleosides and their use as Pharmaceutical Agents in the Prophylaxis or Therapy of Viral Diseases | TYMP, ENTPD5, NUDT1 | DUT 9/4885NLRP3 2626/4885P2RY6 696/4885 |
| US-20140031309-A1 | Beta-L-N4 Hydroxycytosine Deoxynucleosides and their use as Pharmaceutical Agents in the Prophylaxis or Therapy of Viral Diseases | SAMHD1, TYMP, NUDT1 | DUT 8/4885NLRP3 3263/4885P2RY6 1088/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.